In recent years an increase in the diagnosis of early stage and small breast cancers has been reported (Miller et al., 1993; Nab et al., 1993 ). This will be mainly due to the substantial increase in the use of mammography for screening purposes or case finding.
Randomised trials have shown that advanced detection by mammographic screening in women 50 years of age or older can result in a reduction of breast cancer mortality (Hurley and Kaldor, 1992; Fletcher et al., 1993) . The benefit of mammographic screening in younger women is not clear (Fletcher et al., 1993) . This may be owing to factors relating to the screening process itself, such as the sensitivity of the mammographic screening test and the frequency of screening. However, an explanation may also be found in the biology of the tumour. To provide insight into the nature of breast cancer, survival curves by age group and stage of the tumour are compared (Tabiar et al., 1993; Byrne et al., 1994) . A clear trend of increased survival with decreasing size is demonstrated in all age groups. However, small tumours detected by screening mammography may have a lower malignant potential than small cancers detected by the woman herself (Klemi et al., 1992; Tabar et al., 1992) . The malignant potential of breast cancers varies considerably between tumours, one factor being differences in growth rate (Peer et al., 1993 The purpose of mammographic screening is to detect cancers early in their development. However, a lower malignant potential of screen-detected cancers may limit the effectiveness of screening in saving lives. Few data are currently available on the prognosis of patients with small breast cancers, particularly of those detected at screening.
In our study we confirmed, age specifically, the good prognosis of patients with cancers 1 cm or smaller, as was demonstrated in other studies (Rosen et al., 1989; Rosner and Lane, 1990; Tabfar et al., 1993; Byrne et al., 1994) . In the youngest age group only 13% of patients with a tumour diameter of 1 cm or less died of breast cancer within 10 years. Similarly, in the older age groups these failure rates were only 14% and 6% respectively.
On the other hand, the survival advantage for patients with early breast cancers larger than 1 cm differs with age. In the 40-49 age group no significant better breast cancerspecific survival could be demonstrated for patients with a tumour 1.5 or 2 cm in diameter compared with that of patients with a larger tumour of 2.5-4.5 cm. In this age group a substantially better survival is gained only in cases where the tumour is 1 cm or less. For women in the age group 50-69 at diagnosis the break for a better survival is at 1.5 cm tumour size, rising to 2 cm for the > 70 age group, compared with the survival of patients having larger tumours. Thus it seems to be more difficult to improve survival in younger patients. A similar conclusion was reached on the basis of the survival results in the Breast Cancer Detection Demonstration Project (BCDDP) (Byrne et al., 1994) . In the BCDDP this finding was explained by a higher breast cancer survival rate of younger women with a larger tumour compared with that of older women having a tumour of the same size.
This differential effect of age on breast cancer-specific survival of patients with small tumours could explain why it is more difficult to achieve a beneficial effect on breast cancer mortality in women aged 40-49 by mammographic screening. While on the one hand to gain survival advantage in this age group tumours have to be detected when they are very small, on the other hand it is more difficult to spot small malignant tumours in these patients, probably because of their frequently observed dense breast tissue (Ciatto and Zappa, 1993) .
In our study, cancers of a diameter of 1.5 cm or less diagnosed in younger women have a greater potential for fatality than tumours of the same size in older women. This may be partly explained by an earlier metastatic spread indicated by more frequent axillary lymph node involvement. Since 1981, the axillary lymph nodes have been routinely Tumour size (cm) <_ I 42%(n = 26) 15%(n= 100) 25%(n = 36) 1.5 62%(n = 39) 30%(n =79) 21 %(n = 34) 2 45%(n = 38) 43%(n=63) 38%(n = 45) 2.5-4.5 64%(n = 39) 54%(n = 99) 58%(n = 78) )5 91%(n=11) 80%(n=30) 78% (n=23) examined histologically in the two Nijmegen hospitals. Crossclassification of tumour size and lymph node status for the calendar period 1981-92 (see Table III ) shows that younger patients with a tumour of 1.5 cm or less more frequently had lymph node metastasis than older patients with a tumour of the same size. Even after adjustment for nodal involvement in a proportional hazards model, there is still an indication that younger patients with a 1.5 cm or smaller tumour are at greater risk of dying from breast cancer than women in the age groups 50-69 and >70 [hazard ratio 2.7 (P=0.07) and 7.6 (P= 0.06) respectively]. One explanation may be that nodal involvement in older patients is biologically less important regarding risk of distant metastasis compared with node-positive younger patients. This is in line with the recently formulated theory of Hellman (Hellman, 1994) .
Our results indicate that a reduction in breast cancer mortality might be expected in women younger than 50 years of age only if a substantial proportion of the invasive cancers are detected before their size exceeds 1 cm. However, this target is not achieved by film-screen mammography (Peer et al., 1994) . The development of new technologies, such as digital mammography and magnetic resonance imaging, might offer better prospects in this regard. It is also important that small invasive tumours rather than ductal carcinomas in situ are detected at screening, as the proportion of in situ tumours that progress to a life-threatening disease is uncertain.
